Alnylam presents new 18-month results from exploratory cardiac endpoints in helios-a phase 3 study of investigational vutrisiran

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced new positive results from an 18-month analysis of exploratory cardiac endpoints in the helios-a phase 3 study of vutrisiran, an investigational rnai therapeutic in development for the treatment of transthyretin-mediated (attr) amyloidosis. the 18-month findings show that in a pre-defined cardiac subpopulation, treatment with vutrisiran was associated with impro
ALNY Ratings Summary
ALNY Quant Ranking